The recently cloned gene p 16 (MST1) has been idmtified as a putative wmor suppressor gene that binds to , preventing their interaction with eye/in D 1 and thereby preventing cell cycle progression at the G 1 stage. In addition, the p 16 gene has been shoW/! to have a high frequeney of'mutation in some tumor cell lines; however, it has also been shoW/! that a much lower frequency of mutation occurs in primary tumors. This study investigated the mRNA expression level and mutation status of the p 16 gene in ovarian tumors.
T o date, ovarian cancer remains the number one killer of women with gynecologic cancer. Approximately 75% of women are diagnosed with high-stage (Ill and IV) disease. During the past 20 years, neither diagnosis nor 5-year survival have improved greatly. It remains a challenge to develop new markers to detect early disease and to characterize biologic modifiers that will down-regulate metastatic disease.
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The aU(hor~ acknowledge the partlciparion of the followmg div1S.iom of the Cooperativt" Human Tissue Net\-\"ork (CHTN) HI providing turnor (i~sues: W~5Eern Division. Publi~ht'd by Els~v(er Science lnc the phenotypic changes necessary to down-regulate tumor cells. We have imtiated a tumor data base including patients with all grades of ovarian cancer as well as normal ovaries. The data base is intended to document the genes associated with signal transduction, cell-cycle, or ceIl-surface concrol mechanisms that may be insulted (mutated) or whose expression may be modified as a result of the transformation process. Such information may aid the selection of appropriate biologic modifiers for gene therapy. The data base is presently being developed by examining the sequence and expression status of known oncogenes and suppressor genes by isolating mRNA from fresh frozen specimens and using polymerase chain reaction (peR) to examine the products derived from cDNA synthesized from mRNA, We have looked at the expression of p53 and p21 and sequenced pS3 to determine mutations. Our overall findings corroborate other investigations in that approximately 50% of high-stage tumors have p53 mutations and underexpress the p21 gene. We have also begun to evaluate cell-cycle control genes because of their obvious potential in contributing to the growth of tumors that mayor may not 1071-SS76/97/Si i.Ol) rfl SI07t-SS76(97)0004-X have a pS3 mutation. In recent years, many of the genes involved in cell-cycle control have been identified and cloned, and the products of these genes have been documented. 1-. Cyclin-dependent kinases, along with their cyclin-specific counterparts, are responsible primarily for driving the cell cycle past the Gl stage through phosphorylation of the Rb proteinS Once retinoblastoma protein is phosphorylated, it releases the transcription factor E2F, which is required for progression from G l to the S phase of the cell cycle." There also exists a series of suppressors of cell division, which includes p21, p 16, pIS, and pl07 2 -4 Among these suppressors, p16 has been documented as frequently mutated in many cell lines, presumably producing a dysfunctional p 16 protein product, which cannot inhibit the CDK4 and CDK6 kinase reaction l -') More recently, in a series of primary tumors, it has been established that relatively few specimens had documentable mutations in p16. \1)-1 2 In this report, we examine the expression and mutational status of the p 16 gene in ovarian carcinoma with regard to both type and stage of disease.
MATERIALS AND METHODS

Tissue Samples
Ovarian epithelial tumor sapples were obtained from 32 patients. The series consisted of two cases of benign cystadenomas, six cases of cystadenomas of low malignant potential, and 24 cases of cystadenocarcinomas. The clinical stage of all tumors was classified using the International Federation of Gynecology and Obstetrics criteria. Nom1al ovaries were obtained from six patients who underwent surgery for benign gynecologic disease. The tis:>ue samples were obtained immediately after the surgical procedure and were frozen in liquid nitrogen and stored at -80°C.
mRNA Isolation and cDNA Synthesis Extraction of mRNA from the tissue samples and complementary DNA synthesis were perfonned ac cording to the methods we described previously.1 3 Brietly, mRNA was isolated by using a RiboSep mRNA isolation kit (Becton Dickinson Labware). In this procedure, poly A+ mRNA was isolated directly trom the tissue lysate using the at1inity chromatography medium Oligo (dT) Cellulose. The amount of mRNA recovered was quantified by ultraviolet spectrophotometry. The cDNA was synthesized with 5.0 fLg of mRNA by random hexamer priming using the 1 st strand cDNA synthesis kit (Clontech). The efficiency of cDNA synthesis was estimated by using a glyceraldehyde-3-phosphate dehydrogenasepositive control ampliiier (C lontech).
Quantitative peR and Primer Sequences
Quantitative PCR was perfonned ac cording to the method of Nool13n et al1-l with some modifications. The primer sequen ces used in this study were designed according to The products were separated on a 2% agarose gel, and the radioactivity of each band was determined using a Phospho Imager (Molecular Dynamics).
Direct cDNA Sequencing
To prepare the template DNA for the sequencing reaction, we performed PCR with the amplification primers as described earlier. The p16 cDNA was sequenced from (odon 40 to the tem1inal amino acid, covering trorn the middle of exon 1 through the end of exon 3. Amplified cDNA samples were purified using Wizard PCR Prep' DNA purification system (Promega). The sequencing reaction was carried out using a PRISM R eady Reaction DyeOeoxy Tenninator Cycle 5equencing Kit (Applied Biosystems). To remove excess DyeDeoxy, spin columns were used (Princeton Separation). An applied Biosystems Model 373A DNA Sequencing System was used for direct cDNA sequence determilution.
Western Blotting
A protein lysate was prepared frond).5 g of trozen tissue pulverized under liquid nitrogen. We added to the tissue D.S mL of 2 x sodium dodecylsulfate (SOS) sample butler (62.5 mmoUL Tris-HCI, pH 6.8, 4% SD5, 0.01% glycerol, 0.05% 2-~-mercaptoethanol, and ()'()5% bromophenol blue) containing 10 Jl.rnot/L phenylarsine oxide, 2 1111ll0llL sodium o[(hovanadate, 1.3 mmo1!L e thyleneglycol -bis -(~-aminoethyl ether)-N. N, N', N' -tetra-acetic acid, and 100 Jl. moUL trifluoperazine. The sample was placed in a boiling water bath for 5 minutes and thereafter was centrifuged at 1 C),DOO rpm for 10 minutes. The supematant at 50 fLg protein/ lane was used tor electrophoresis on a 13% SOS polyacrylamide gel.
Proteins were transferred electrophoretically to PVDF membranes (Bio-RaJ) for 20 hours at 30 v. Membranes were P 16 Overexpression in Ovarian Cancer blocked with nonfat milk, incubated \vith 4 J.lg/ mL purified anti-human p16 'NK4 monoclonal antibody (Pharmingen) lor 3 hours, incubated with goat anti-mouse IgG horseradish peroxidase complex (Bio-Rad), and developed with horseradish peroxidase color development reagent (Bio-Rad).
Immunohistochemistry
Immunohistochemical staining \vas performed using a Vectastain Elite ABC kit (Vector). Formalin-fixed and parafiinembedded specimens were routinely deparaffinized and incubated in methanol with 0.3% H 2 0 2 for 30 minutes at room temperature to block endogenous peroxidase activity. After treatment, the samples were incubated with 10 J.lg/mL purified anti-human p16 'NK4 monoclonal antibody (Pharmagen) for 18 hours at 4°C in a moisture chamber, incubated with biotinylated anti-mouse IgG (Vector) for 30 minutes at room temperature, and thereafter incubated with ABC reagent (Vector) for 30 minutes at room temperature. The final produ cts were visualized by using diaminobenzidine (0.2 mg/mL) in the presence of 0.003% H Z02' and sections were counterstained \vith 1% methyl green before clearing and mounting. Negative controls were performed by substituting nonimmune serum for the primary antibody.
RESULTS
Quantitative peR of p16 Expression
To detemline the number of PCR cycles appropriate lor quantification, we monitored PCR amplitication fiom cycle 15 through cycle 35 every five cycles. Lineariry of the f)-tubulin gene and pl6 gene PCR products was consistent over 30 cycles ( Figure I) , and therefore 30 cycles of PCR was used routinely for expression of the p 16 gene.
To compare the expression of pl6 in normal and ovarian carcinoma tissues, we perfomled PCR amplification using a f3-tubulin internal standard. '3 Oligonucleotide primers used for co-amplification of p 16 and f3-tubuIin are given in Materials and Methods. Several genes were tested as internal controls, and f3-tubulin was the most satislactory. Actin was found to be overexpressed in carcinoma by two-to lourfold and was (log) 8 J Soc Gynecollnvest Vo!. 4, No, 2, Mar.lApr, 1997 97 not used for this reason. Glyceraldehyde 3-phosphate dehydrogenase was consistently expressed, but was so highly expressed relative to most genes that relative expression determinations were difficult for genes of average or low expression. Beta-tubulin was found to be the most consistently expressed in normal and carcinomatous tissues and was not so highly expressed as to compromise the evaluation of comparison genes of low or average expression. We examined the relative expression oi the p 16 gene ti-om six normal ovarian ti>sues, two benign adenomas, six adenomas oflow malignant potential, and 24 ovarian carcinomas ( Figure  2 ). The relative expression ofpl6 to f3-tubulin was elevated in most ovarian tumors (28 of 32 or 88,};,) compared with norlllal ovaries). Expression ofp16 in IllOst tumors (26 of32. SI'X» was four or more standard deviations above the mean for the nor- * Dverexpression = +2 SD or greater over the mean normal values. 7 Including endometrioid, dear-ee1l. and mucinous. mal ovary. Figure 3 compares p16 expression in normal ovarian tissue versus ovarian carcinoma. Five of six low malignant potential tumors (83%) and 22 of24 carcinomas (92%) showed overexpression (Table 1) . With respect to clinical stage of disease, three of four (75%) stage I-II carcinomas and 19 of 20 (95%) stage Ill-IV carcinomas showed significant p16 mRNA elevation ( Table 1) . One of the two benign adenomas examined also exhibited p 16 overexpression. Normal levels of p 16 were found in only one adenoma, one mucinous adenoma of low malignant potential, and two serous carcinomas.
p16 Mutations
To determine whether the overexpression of p 16 could be related to mutation resulting in dysfunction of the cell-cycle inhibitor, we sequenced the PCR-amplified products of the p16 gene for all 38 specimens. The pl6 gene \vas amplified using two sets of primers (see Materials and Methods) that extended from the middle of exon I (amino acid 40) through the end of exon 3. This area encompasses the knmvn mutations already described for p16. No mutations were discovered in the six normal specimens. Four sequence alteratiom were discovered in the 32 tumor specimens ( Table 2) . A benign tumor (case 8) showed a G to T transversion in codon 127, which has previously been described as a polymorphism. I I One tumor oflow malignant potential (case 9) and one ovarian cancer (case 24) showed the same G to A transition in codon 148, a known polymorphism.H.lo.ll One low malignant potential tumor (caseJ2) showed a G to A transition in codon 68. This base change, however, does not alter the amino acid sequence of the pl6 protein. Overexpression of p16 and base Table 3 , indicating an overexpression rate of 88% (28 of 32) in ovarian tumors with four cases of base alteration, including three known polymorphisms and one mutation without an amino acid sequence change.
Western Blot p16 Expression
To confirm that p16 mRNA overexpression results in an actual accumulation of the p16 protein, {WO tumor cases that had demonstrated overexpression of p 16 mRNA were examined by comparing them with normal ovarian tissue by Western blot. Both samples showed overexpression of p16 protein compared with normal ovarian tissue. In Figure 4 
Immunohistochemistry
To confirm that p 16 overexpression was actually occurring in tumor cells and not in the underlying stromal or vascular tissue, we also examined p16 expression using immunohistochemical staining of paraffin-embedded, tormalin-fixed sections of normal ovary and ovarian carcinoma ( Table 4 ). Five normal ovarian tissues, four low malignant potential tumors, and 15 carcinomas were examined using immunohistochemistry. All four of the low malignant potential tumors and 14 of 15 of the carcinomas showed increased staining for p16 ( Figure SC, D) . One clear-cell carcinoma had a weak positive staining similar in intensity to that detected in two of the five normal ovarian epithelial specimens ( Figure SA, B) . A comparison ofp16 expression examined by both quantitative PCR and immunohistochemistry confirms the efficacy of both approaches in demonstrating the overexpression of p 16 III both low malignant potential and invasive ovarian carcinomas ( Table 5 ).
DISCUSSION
It is now evident that the progression of cells through the cell cycle is regulated by positive signals (cyclins and cyclindependent kinases) and negative signals (eyelin-dependent kinase inhibitors such as p21 and p16).2-4 Thus, p16 binds to CDK4/f> and lI1hibits the catalytic activity of cyclinDI Figure 6 ). In this manner, pl6 could Jct as a cumor suppressor gene. Conflicting results have been reported concerning the frequency of p 16 mutations. It has been reported that p 16 homozygous deletions were found frequently in cell lines derived from a ,vide variety of human tumors, including lung, breast, brain, skin, bladder, kidney, and ovary, as \vell as in leukemia and me!anoma H -') However. it has also been reported that the frequency of intragenic p 16 l1lutations was quite low in primary tumor samples of lung, brain, bladder, kidney, ovary, Jiver, colon, and head and neck. Table 3 ), age (approximately 90%) of high-stage carcinomas appeared to overexpress the p16 gene as assessed by quantitative PCR and confirnled in selected cases by both Western blot and immunohistochemistry. These data therefore mggest not only that mRNA is overexpressed, but also that this is translated effectively into a p 16 product that presumably accumulates in the cytoplasm of carcinoma cells. Furthennore, sequencing of the p 16 gene from this series of tumor, demonstrates that no alteration in amino acids occurred, and therdore the protein product of this overexpressed mRNA gene is a putatively functional wild-type product that presumably has the capacity to bind to CDK4 and CDK6. Such a SItuation, of COUT>e, is paradoxical because these malignallt carcinomas are highly proliferative and obviously freely and frequently pass through the cell cycle without regard to the regulatory capacity of this 
-Cell Cycle Progression
IGt -S) Figure 6 . Cyclin D and CDK4/6 stimulate cdl division by phosphorylating Rb (retinobbstoma) protein A transcription factor such as E2F is released and activates the transition from G 1 to S phase. pi 6 binds to the catalytic subunit CDK4 or CDK6 and inactivates the cyclin D-CDK4/6 complex. E2F released from Rb may also activate the transcription of pi 6. overexpressed p 16 protein. Although the obvious conclusion might have been that p16 was mutated, this was not the case.
As such, the data point to some downstream dysfunction that allows continued cell-cycle progression without regulation. Several potential candidates may be suggested for this downstream dysfunction, which would allo\v constitutive cell cycling in the face of overexpressed levels of pl6 ( Figure 6 ) .
They are as fo!lo\vs: 1) a defect in the cyclin-dependent kinase that would prevent p 16 blllding and therefore downregulation ; 2) the activation of an altemate pathway to phosphorylate the Rb protein and therefore bypass p 16 regulation;
3) a defect in the Rb protein that allows it to be constitutively active and therefore not regulatable; 4) an incapacitated phosphatase that allows continued activitv of the Rb protein due to its hyperphosphorylation and the loss of capacity to be dephosphorylated and reassociated with E2F. 5) a defect in the Rb or E2F transCliption tIctor that would not allow dimerization of the hypophosphorylated form and therefore inactivation of the complex; 6) an endogenous binding protein that inactivates p 16 and prevents it trom binding to CDK2 and CDK4; or 7) overexpression of cyclin D and CDK4 and CDK6, which would override and outperform th e inhibitory eHeets of the high levels of pl6 present. It should be pointed out that although the predominant observation wa, overexpression of p 16 in mmt tumors, then> were three tumoTS that did not overexpress the p 16 gene; these su ggest the existence of another matrix of genetic insults that may be implicated in ovarian cancer. At present, there are 110 data to suggest what this combination of iilStdts might be, but it is possible that some small group of the tumors do not include th e phenomenon of pH) overexpression. Although there lTIay be insufficient data to conclude that J Soc Gynecol Invest Vol. 4, No. 2, Mar.lApr. 1997 101 P 16 dysfunction is an early consequence in the transformation process, and may actually precede it, such an indication may be possible. It could be viewed as an early loss of cell-cycle control, which would allow low malignant potential growth or benign growth and therefore could be a contributing factor to the downstream potential for metastatic and pervasive growth . The data indicated overexpression in most low malignant potential tumors and in one of two benign tumors. Clearly, further evaluation and a more extensive study in this area are warranted. Loss of control of the cell cycle at the G I interface through lack of control of pl6 appears to precede the muta-tiollS that occur in pS3, resulting in underexpression of p21 and subsequent loss of co ntrol of the cell cycle. More recently, the pIS gene, a close relative of p 16, has also been described, although its role in ovarian carcinoma is still unclear. 15 In addition, hypermethylation of the p 16 gene in CPG islands has been demonstrated as contributing to the reduced expression of this gene, and therefore hypo methylation may be a factor in the overexpression noted here. I" Because p 16 is overexpressed in most ovarian tumors-both lo,"v malignant potential and high-grade disease--there is no obvious correlation between p 16 overexpression and pS3 mutation or p21 underexpression . Overexpression of p 16 is both an earlier event in the development of these ovarian carcinomas and is manifest in a lTIuch higher percentage of tumors than is pS,") mutation or p21 underexpression. To clarify this paradox. we will continlle to evaluate the downstream factors already mentioned in this discussion in an attempt to e1l1cidate the relations between a dysfunctional cell-cycle control system and overexpression of p 16 in ovarian carcinoma.
